Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

56.63
+0.13000.23%
Post-market: 55.58-1.0500-1.85%19:52 EDT
Volume:1.88M
Turnover:106.50M
Market Cap:10.83B
PE:-13.83
High:57.49
Open:56.63
Low:55.71
Close:56.50
52wk High:57.49
52wk Low:21.72
Shares:191.17M
Float Shares:151.20M
Volume Ratio:0.76
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0935
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-41.96%
PB:-6.06
PE(LYR):-19.67

Loading ...

Neil Kumar, Chief Executive Officer, Reports Disposal of Common Shares of BridgeBio Pharma Inc

Reuters
·
Aug 23

BridgeBio Pharma's President and CFO, Thomas Trimarchi, Reports Disposal of Common Shares

Reuters
·
Aug 20

Helix Acquisition Corp. II Releases Proforma Financials Highlighting BridgeBio Oncology Therapeutics Merger

Reuters
·
Aug 13

Director Charles J. Homcy Reports Disposal of Common Shares in BridgeBio Pharma Inc

Reuters
·
Aug 13

CEO Neil Kumar Reports Disposal of BridgeBio Pharma Inc. Common Shares

Reuters
·
Aug 12

BridgeBio Pharma Inc : Mizuho Raises Target Price to $64 From $60

THOMSON REUTERS
·
Aug 11

Director Andrea Ellis Reports Disposal of BridgeBio Pharma Inc. Common Shares

Reuters
·
Aug 08

BridgeBio Pharma Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
Aug 07

Stock Track | BridgeBio Pharma Plummets 11.93% Pre-market on Wider-Than-Expected Q2 Loss

Stock Track
·
Aug 06

BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $62 From $56

THOMSON REUTERS
·
Aug 06

BridgeBio Pharma, Inc. : Oppenheimer Raises Target Price to $61 From $60

THOMSON REUTERS
·
Aug 06

Helix Acquisition Corp. II Retains Over 60% of Trust Account Post-Redemptions, Securing $382 Million for BridgeBio Oncology Merger

Reuters
·
Aug 06

Helix Acquisition Corp. Ii Retains More Than 60% of Trust Account After Redemptions in Connection With Business Combination With BridgeBio Oncology Therapeutics

THOMSON REUTERS
·
Aug 06

BridgeBio Pharma Inc : Scotiabank Raises Target Price to $57 From $55

THOMSON REUTERS
·
Aug 06

Stock Track | BridgeBio Pharma Plunges 11.40% Pre-market Following Wider-Than-Expected Q2 Loss

Stock Track
·
Aug 06

Stock Track | BridgeBio Pharma Plunges 14% After Reporting Wider-Than-Expected Q2 Loss

Stock Track
·
Aug 06

Stock Track | BridgeBio Pharma Plunges 10% After Hours on Wider Q2 Loss Despite Revenue Beat

Stock Track
·
Aug 06

BridgeBio Pharma Shares Down in After-Hours Trading Following Results, Last Down 12% at $42.93

THOMSON REUTERS
·
Aug 06

BridgeBio Pharma Inc. Unveils Corporate Presentation Highlighting FDA Approvals and Advancements in Key Clinical Trials

Reuters
·
Aug 06

BridgeBio Pharma Reports Q2 2025 Revenue of $110.6M; Net Loss Widens to $181.9M, EPS Drops to $0.95

Reuters
·
Aug 06